Upstate Active Clinical Trials

Study Title:

A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination to insulin glargine with or without metformin in patients with T2DM

What is the purpose of the study?

The study is being conducted to see if an investigational drug combining insulin glargine and lixisenatide, can improve blood glucose in people with type 2 diabetes more effectively than with insulin glargine alone.

Upstate Institutional Review Board (IRB) Number:

566456

Study/Protocol ID:

EFC12405

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

What is involved if I participate?

  • How long is the study?
    39 weeks
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Procedures during study visits include: physical exams, vital signs, blood collection, urinalysis, ECG, questionnaire completion. Subjects will be asked to keep a diary of blood glucose readings throughout the study.

Where will the study take place?

Clinical Research Unit at IHP (505 Irving Ave.)

Other Information:

Study medications in pen form will be provided for the length of the study, along with a glucose meter and testing supplies.

ClinicalTrials.Gov ID:

NCT02058160

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu

Return to Previous Page || Search Again